The Expression Of A-B Crystalline In Triple-negative Breast Cancer And Significance Of Targeted Therapy

Objective:a-B crystallin is one of the small heat shock protein family,and its basic functions as a chaperone-involved in protein folding,composition and activity regulation of heat shock protein, but recent studieshave shown that its close relationship with some of the tumor, and take part intumorigenesis, development and prognosis. Fas protein, as the tumor necrosisfactor receptor superfamily a series of intracellular signaling cascadesactivated by combining its receptor Fasl induce apoptosis. Fas/Fasl system isan important way of apoptosis. When some of the factors that caused thesignal cascade is blocked, you can not induce tumor cell apoptosis. Triplenegative breast cancer is a special subtype of breast cancer, its estrogenreceptor, progesterone receptor and human epidermal growth factor receptor2are all negative.Because of its poor prognosis, prone to distant metastases, notsensitive to radiotherapy and endocrine treatment, the survival rate is low,soits treatment are still dependent on surgery and adjuvant chemotherapy. Thetreatment of triple negative breast cancer is relatively limited,and its poorprognosis.So enrich the treaments of the triple negative breast cancer,researchand develop new drugs of the triple negative breast cancer,improve itsprognosis and prolong patients survival has become a focus in the study ofpeople.The purpose of this paper is to study a-B crystallin expression in triplenegative breast cancer, by the analysis of a-B crystalline in breast cancerclinical and pathological correlation between the indexes, and discuss the rolein the prognosis of triple negative breast cancer; and explore its mechanism ofaction is related to block the Fas/Fasl system inhibition of apoptosis, and thenanalyze whether a-B crystalline can be used as a target of targeted therapy intriple negative breast cancer, and provide new research directions for triplenegative breast cancer’s clinical diagnosis, prognosis and treatment. Method: By immunohistochemistry (Immunohistochemistry, IHC) SPassay our hospital pathology confirmed80cases of breast cancer (30cases oftriple negative breast cancer, paraffin-embedded specimens of50cases ofnon-triple negative breast cancer) in the biopsy tissue a-B crystallin, Fas/Faslligand system and positive expression rate comparison a-B crystallin, Fas/Fasl expression whether triple negative breast cancer and non-triple-negativebreast cancer organization, to analyze the correlation relationship between thea-B crystallin expression with triple negative breast cancer clinical andpathology indicators,and on a-B crystal protein expression with Fas/Faslexpression for correlation analysis.Results:1a-B crystallin expression in different breast cancer groupa-B crystallin in triple negative breast cancer positive expression rate was66.67%(20/30),and its expression in non-triple negative breast cancer rate is42.00%(21/50), indicating that in triple negative breast cancer wassignificantly higher than the non-triple negative breast cancer (X2=4.566, P<0.05)A-B crystallin strongly positive expression rate was75.00%(15/20), thenon-triple negative breast cancer strongly positive expression rate of triplenegative breast cancer (6/21)28.57%. The expression of both rate difference(X2=17.25, P <0.01)2Fas/Fasl expression in different breast cancer group:Fas positive expression in triple negative breast cancer group was40.00%(12/30), in the expression of non-triple negative breast cancer group was56.00%(28/50), two sets of expression rates showed no significant difference(X2=1.92, P>0.1)Fasl positive expression in triple negative breast cancer group was86.67%(26/30), in the expression of non-triple negative breast cancer groupwas72.00%(36/50), two sets of expression was no significant difference (X2=2.31, P>0.05) 3In triple negative breast cancer, a-B crystal protein and Fas hascorrelation (Χ2=5.625, P <0.05, r=-0.433), there is a negative correlation;A-B crystal protein and Fasl has correlation (Χ2=9.231, P <0.05) there arepositive correlation; Fas and Fasl have correlation (Χ2=7.579, P <0.05, r=-0.183), there are negative correlation.4The expression of a-B crstallin in breast cancer and its relationshipbetween the clinical and pathological indicatorsthe expression of a-B crystallin in breast cancer has no significantdifferent(P＞0.05)，no obvious difference with tumor diameter (P＞0.05), hasdifference with Lymph node metastasis (P＜0.05), has difference with thenumber of lymph node metastasis (P＜0.05), no significant difference withcancer stage (P＞0.05), has difference with P53(P＜0.05) and has a positivecorrelation (r=0.324), has difference with Ki67(P＜0.05) has a positivecorrelation (r=0.251).5The expression of a-B crstallin in triple negative breast cancer and itsrelationship between the clinical and pathological indicatorsthe expression of a-B crystallin in triple negative breast cancer has nosignificant different(P＞0.05)，no obvious difference with tumor diameter (P＞0.05), no obvious difference with Lymph node metastasis (P＞0.05), noobvious difference with the number of lymph node metastasis (P＞0.05), nosignificant difference with P53(P＞0.05), no significant difference withcancer stage (P＞0.05), no significant difference with Ki67(P＞0.05).Conclusion:1A-B crystallin expression differences between triple negative andnon-triple negative breast. A-B crystallin is highly expressed in triple negativebreast cancer, a higher rate of expression in triple negative breast cancerlymph node metastasis.2A-B crystalline is associated with poor prognosis of breast cancer, anda-B crystallin high expression in triple negative breast cancer may be one ofthe reasons for the triple negative breast cancer with poor prognosis.3The expression of fas/fasl between the triple negative and non-triple negative breast cancer is no difference, but low expression of fas and faslexpression, the apoptotic signal expression imbalance consider breast canceroccurred transfer certain.4The combined expression of a-B crystallin and Fas/Fasl in triplenegative breast cancer may contribute to the development of triple negativebreast cancer, metastasis, a-B crystalline may become a new target for triplenegative breast cancer targeted therapy.